Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,466.00
Bid: 12,464.00
Ask: 12,466.00
Change: -44.00 (-0.35%)
Spread: 2.00 (0.016%)
Open: 12,556.00
High: 12,562.00
Low: 12,420.00
Prev. Close: 12,510.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sterling eases off recent highs as investors temper vaccine optimism

Thu, 28th Jan 2021 09:22

* Graphic: World FX rates in 2020 http://tmsnrt.rs/2egbfVh

* Graphic: Trade-weighted sterling since Brexit vote http://tmsnrt.rs/2hwV9Hv

LONDON, Jan 28 (Reuters) - The British pound retreated on
Thursday from the multi-month highs it hit in the previous
session, as investors tempered some of their optimism about
COVID-19 vaccinations in the UK.

Sterling surged to its highest since May 2018 against the
dollar in early London trading on Wednesday and later hit an
eight-month high against the euro - a move analysts attributed
to the UK's vaccine rollout being faster than that of Europe.

But the British currency gradually eased off these highs,
falling overnight and opening lower on Thursday.

At 0850 GMT, it was down 0.4% against a stronger dollar, at
$1.3638, compared to its Wednesday high of $1.3759.

Versus the euro, it was down around 0.3% at 88.67 pence per
euro, having peaked at 88.135 in the previous session
.

"We consider Sterling optimism to be excessive and we see
the risk of disappointed expectations. We therefore urge caution
about betting on further Sterling gains," wrote Commerzbank FX
strategist You-Na Park-Heger in a note to clients.

"The markets are clearly ignoring that the current infection
situation in the UK is still very tense," she said.

"There is a high degree of uncertainty as it is difficult to
say how the pandemic is going to develop short-term and when and
how quickly the restrictions can be eased," she added.

Britain has the world's fifth highest death toll from
COVID-19 and Prime Minister Boris Johnson has indicated that the
strict COVID-19 lockdown in England will last until March 8.

The pound has strengthened since a last-minute Brexit deal
was reached in December 2020. But Commerzbank's Park-Heger said
that the impact of Brexit on the UK's economy is still unknown.

The possibility of the Bank of England cutting rates
presents another downside risk for the pound, she said.

Britain said on Thursday that it must receive all of the
COVID-19 vaccines it had ordered and paid for, after some
European Union politicians asked drugmaker AstraZeneca to divert
doses from the UK to make up for a shortfall in supplies.

AstraZeneca was the top drag to the FTSE 100 index
for the second consecutive day.

But some analysts took a positive tone: "The political
jitters between the EU, AstraZeneca and the UK don’t appear to
have a negative impact on GBP. We look for further EUR/GBP
decline over the course of the year as the UK vaccination
advantage (and its likely earlier recovery) and GBP
undervaluation vs EUR are to benefit sterling," wrote ING
analysts in a note to clients.
(Reporting by Elizabeth Howcroft, Editing by William Maclean)

More News
27 Nov 2023 09:20

LONDON BROKER RATINGS: Peel, Numis up Rightmove; Goldman cuts Entain

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
23 Nov 2023 18:41

IN BRIEF: AstraZeneca Chair Demare buys shares for over GBP200,000

AstraZeneca PLC - Cambridge-based pharmaceutical company - Chair Michel Demare buys 2,000 shares in total on Wednesday and Tuesday. Buys 1,000 shares for GBP101.05 each on Tuesday and 1,000 shares for GBP101.70 each on Thursday, for a total of GBP202,752.

Read more
20 Nov 2023 10:49

AstraZeneca launches new life sciences tech innovation firm Evinova

(Alliance News) - AstraZeneca PLC on Monday launched Evinova, a new health technology business focused on accelerating innovation across the life sciences sector, delivery of clinical trials and better health outcomes.

Read more
17 Nov 2023 15:20

London close: Stocks higher despite weaker retail sales data

(Sharecast News) - London's stock markets finished in a positive state on Friday despite weaker-than-expected UK retail sales figures.

Read more
17 Nov 2023 12:00

LONDON MARKET MIDDAY: Stocks shrug off downbeat UK retail sales

(Alliance News) - Stock prices in London were up at midday on Friday, as a week of favourable data as far as inflation goes gave investors a reason to overlook disappointing UK retail sales figures.

Read more
17 Nov 2023 09:03

LONDON MARKET OPEN: Stocks up despite UK retail sales growth miss

(Alliance News) - Stock prices in London opened higher on Friday, despite weaker-than-expected October retail sales figures for the UK.

Read more
17 Nov 2023 08:31

TOP NEWS: US approves AstraZeneca's Truqap for form of breast cancer

(Alliance News) - AstraZeneca PLC on Friday said that the US Food & Drug Administration approved its drug Truqap in combination with Faslodex to treat patients with an advanced form of breast cancer.

Read more
17 Nov 2023 07:58

LONDON BRIEFING: UK retail sales fall; AstraZeneca gets US approval

(Alliance News) - Stock prices in London are still set to open higher on Friday, despite October retail sales figures for the UK disappointing shortly before the opening bell.

Read more
17 Nov 2023 07:16

AstraZeneca gets US approval for breast cancer treatment

(Sharecast News) - AstraZeneca's 'Truqap', or capivasertib, in combination with 'Faslodex', or fulvestrant, has secured approval from the US Food and Drug Administration (FDA) for specific breast cancer treatments, the company announced on Friday.

Read more
14 Nov 2023 10:51

TOP NEWS: AstraZeneca Imfinzi fails to meet endpoint in cancer trial

(Alliance News) - AstraZeneca PLC on Tuesday said the Pacific-2 phase III trial for Imfinzi as an early treatment lung cancer immunotherapy treatment administered with chemoradiotherapy, did not meet its primary endpoint.

Read more
14 Nov 2023 09:22

AstraZeneca's latest lung cancer trial fails its primary endpoint

(Sharecast News) - AstraZeneca announced on Tuesday that its 'PACIFIC-2' phase three trial for Imfinzi, or durvalumab, concurrently administered with chemoradiotherapy (CRT), did not achieve its primary endpoint of progression-free survival compared to CRT alone.

Read more
13 Nov 2023 09:45

LONDON BROKER RATINGS: Diageo gets price target cuts; JPMorgan ups M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning:

Read more
9 Nov 2023 15:02

London close: Stocks gain as investors await Powell speech

(Sharecast News) - London's stock markets were buoyant at the close of trading on Thursday, influenced by Chinese inflation data, a substantial influx of corporate news, and a speech from the Fed chair later in the global day.

Read more
9 Nov 2023 12:06

LONDON MARKET MIDDAY: FTSE up despite higher for longer US rates fear

(Alliance News) - European equities were on the up on Thursday, despite lingering US interest rate worries and poor China data.

Read more
9 Nov 2023 11:02

Lancashire Holdings declares special dividend after strong year so far

(Alliance News) - Lancashire Holdings Ltd on Thursday said it approved a capital return of up to USD169 million, and it reported rising gross premiums written for the year-to-date.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.